Related Experiment Videos
Changes in some hemostatic parameters in patients with infections treated with ceftazidime and latamoxef
A Gabryelewicz1, J Prokopowicz, N Wołosowicz
1Department of Gastroenterology, Medical School, Białystok, Poland.
Abstract:
In comparative studies made in patients with pneumonia we have treated 14 cases with Latamoxef and 16 cases with Ceftazidime. We have concentrated our attention on the side effects of these drugs on hemostasis. In 8 patients treated with Latamoxef we have found a prolongation bleeding time, moderate hypoprothrombinemia, thrombocytopenia and nearly no normalization of APTT and plasma euglobulin fibrinolysis. In one patient treated with Ceftazidime only slight effect of this drug on hemostasis was observed. Crucial reason for coagulopathy is probably due to impaired synthesis of vitamin K by diminished gut flora conditioned by antibiotics treatment. In the case of Ceftazidime mentioned there seem to be minimal side effects.
Insights
Latamoxef significantly impacted patient hemostasis, causing bleeding issues and low platelets. Ceftazidime showed minimal side effects on blood clotting, suggesting it is a safer antibiotic option for pneumonia patients.
Area of Science:
- Pharmacology
- Hematology
- Infectious Diseases
Background:
- Antibiotic therapy is crucial for treating pneumonia.
- Understanding drug-induced hemostatic complications is vital for patient safety.
- Latamoxef and Ceftazidime are antibiotics used in pneumonia treatment.
Purpose of the Study:
- To compare the hemostatic side effects of Latamoxef and Ceftazidime in pneumonia patients.
- To identify potential risks associated with antibiotic use on blood coagulation.
Main Methods:
- Comparative study involving 14 patients treated with Latamoxef and 16 with Ceftazidime.
- Monitoring of bleeding time, prothrombin time, platelet count, activated partial thromboplastin time (APTT), and fibrinolysis.
- Assessment of drug-induced coagulopathy.
Main Results:
- Latamoxef treatment led to prolonged bleeding time, hypoprothrombinemia, and thrombocytopenia in 8 patients.
- Latamoxef also showed minimal normalization of APTT and fibrinolysis.
- Ceftazidime exhibited only slight effects on hemostasis in one observed patient.
Conclusions:
- Latamoxef poses a significant risk of hemostatic side effects in pneumonia patients.
- Ceftazidime appears to have minimal impact on hemostasis, indicating a potentially safer profile.
- Antibiotic-induced coagulopathy may stem from impaired vitamin K synthesis due to gut flora disruption.